TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05993949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
Study: NCT06476002

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
Study: NCT06271200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting and 10,000 steps per day
Description: Reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis plus walking more than 10,000 steps per day.
Study: NCT05864924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort A: 3.0x10^6 CAR-T cells/kg
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort B: 9.0x10^6CAR-T cells/kg
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort C:1.5x10^7 CAR-T cells /kg
Description: Intravenous infusion
Study: NCT05322863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition Transcranial Direct Current Stimulation
Description: The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
Study: NCT05643404

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardioghaphy
Description: Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardioghaphy
Description: Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
Study: NCT05276531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: clinical pregnancy rates

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: clinical pregnancy rates
Study: NCT05880316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: 3:4 regime
Study: NCT04089046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM-UP for Teens
Description: TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care (EC)
Description: Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
Study: NCT06273462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 600mg twice a day
Description: 600mg palmitoylethanolamide twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: visually identical placebo capsule
Study: NCT05652530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
Description: This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
Study: NCT05322863

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition Transcranial Direct Current Stimulation
Description: The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
Study: NCT05994794

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-GPC, Creatine and Ashwagandha (Sensoril®)
Description: Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study: NCT01449357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: IV infusion, 16mg/kg on weekly basis until DP
Study: NCT05302739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial cooling
Description: 30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
Study: NCT05671952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of integrated intervention system programs
Description: Application of integrated intervention system programs
Study: NCT06642090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients undergoing hemodialysis in Morocco
Description: This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
Study: NCT06198400

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye
Description: The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
Study: NCT06639685

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MR Fingerprinting and ASL
Study: NCT05888922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Tablets
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Topical
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle solution
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle solution
Description: The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
Study: NCT06563986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic treatment (FTD-TPI and bevacizumab)
Description: Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with 166-Ho microspheres
Description: Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated.
Study: NCT06565013

Intervention type: DRUG
Intervention: Cabenuva 600/900
Description: Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.

Intervention type: OTHER
Intervention: Self administered questionnaires
Description: Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11

Intervention type: OTHER
Intervention: Semi-directed interview
Description: At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
Study: NCT06584799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized purified flavonoid fraction
Description: Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin 600
Description: Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
Study: NCT05964673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioptron light therapy
Description: patients will receive patient education program and bioptron light therapy for four weeks
Study: NCT05416099

Intervention type: PROCEDURE
Intervention: laser
Description: grid vs micropulse laser

Intervention type: PROCEDURE
Intervention: laser
Description: grid vs micropulse laser
Study: NCT03878953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
Study: NCT05086809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device A
Description: Participant wear Device A and evaluate the performance of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device A
Description: Participant wear Device A and evaluate the performance of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device B
Description: Participant wear Device B and evaluate the performance of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device B
Description: Participant wear Device B and evaluate the performance of the device.
Study: NCT05593952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task
Description: exercise with dual task + usual treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single task
Description: exercise without dual task + usual treatment.
Study: NCT05082649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face Exercise
Description: Face to face (in clinic) progressive spinal stabilization exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Remotely (with video) progressive spinal stabilization exercises.
Study: NCT06173570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: AZD0780 administered orally, once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, once daily for 12 weeks
Study: NCT04688047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing care based on the transtheoretical model
Description: Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
Study: NCT05436132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR and AR oral healthcare curriculum training
Description: HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: traditional teaching methods oral healthcare curriculum
Description: HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
Study: NCT04282239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS2 block
Description: Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 15 mL on each side of anterior chest for a total of 30mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: 10 mL on each side of anterior chest for a total of 20mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.004 MG/ML
Description: 10 mL
Study: NCT05945810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 extended-release tablet
Description: 50mg TLL-018 extended-release tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 extended-release tablet
Description: 50mg TLL-018 extended-release tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 immediate-release tablet
Description: 20mg TLL-018 immediate-release tablet BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 immediate-release tablet
Description: 20mg TLL-018 immediate-release tablet BID
Study: NCT05949099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
Study: NCT06554392

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample from each subject to detect Glutathione Peroxidase 4.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample from each subject to detect Glutathione Peroxidase 4.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample from each subject to detect Glutathione Peroxidase 4.
Study: NCT06584799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin+Diosmin combination 1000
Description: A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months
Study: NCT06507956

Intervention type: OTHER
Intervention: Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis
Description: Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive/hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
Study: NCT04518228

Intervention type: DRUG
Intervention: Bictegravir (BIC)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Tenofovir alafenamide (TAF)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants

Intervention type: DRUG
Intervention: Tenofovir alafenamide (TAF)
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
Study: NCT05920694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure Device (CPAP)
Description: Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Continuous Positive Airway Pressure Device (CPAP)
Description: Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
Study: NCT06253884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
Study: NCT06292234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSI
Description: Fabrication of PSI implants using virtual surgical planning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional miniplates
Description: Ready made miniplates